Endocrinologia, Diabetes y Nutricion最新文献

英文中文

Lipid management in individuals with type 2 diabetes mellitus: Analysis of a hospital-based series 2型糖尿病患者的脂质管理：基于医院系列的分析

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-10-03 DOI: 10.1016/j.endinu.2025.501674

João D. Martins, Débora Silveira, Henrique Pina, Inês Manique, Sílvia Guerra, Cristina Valadas

Background and aims

People with type 2 diabetes (T2DM) face higher cardiovascular risk, making lipid control essential. The European Society of Cardiology (ESC) updated its clinical practice guidelines in 2023, introducing the SCORE2-Diabetes risk calculator. This study evaluates lipid control, lipid-lowering therapy, and CV risk reclassification in full compliance with the 2021 and 2023 ESC clinical practice guidelines.

Methods and results

We analyzed T2DM patients (40–69 years) treated at our hospital Endocrinology-Diabetes outpatient clinic from January through October 2023. Hospital records and the Portuguese National Health System database were used to assess CV risk, LDL-c target achievement, risk classification changes, and lipid-lowering therapy, including statin potency. The study included a total of 214 individuals (mean age, 58.5 years; 61.2% men). Under the 2021 ESC clinical practice guidelines, a total of 38.3% patients were categorized as very high risk, 51.9% as high risk, and 9.8% as moderate risk, with LDL-c targets met in 22.0%, 29.7%, and 47.6%, respectively. Under the 2023 clinical practice guidelines, 43.0% were very high risk; 25.7%, high risk; 24.8%, moderate risk; and 6.5%, low risk, with LDL-c targets met in 21.7%, 29.1%, 54.7%, and 71.4%, respectively. Risk classification changed for 32.7% of patients. Regarding treatment, 23.83% were not on lipid-lowering therapy, while 26.17% used high-intensity statins.

Conclusion

Lipid control in T2DM remains suboptimal, especially in high-risk patients. While improvements are being made, tools such as the SCORE2-Diabetes may improve individualized treatment and reduce cardiovascular events.

背景和目的2型糖尿病（T2DM）患者有较高的心血管风险，因此控制血脂至关重要。欧洲心脏病学会（ESC）于2023年更新了其临床实践指南，引入了score2 -糖尿病风险计算器。本研究完全按照2021年和2023年ESC临床实践指南评估血脂控制、降脂治疗和CV风险重新分类。方法和结果我们分析了2023年1月至10月在我院内分泌-糖尿病门诊治疗的2型糖尿病患者（40-69岁）。使用医院记录和葡萄牙国家卫生系统数据库来评估CV风险、LDL-c目标实现情况、风险分类变化和降脂治疗，包括他汀类药物效力。该研究共纳入214人（平均年龄58.5岁，男性61.2%）。根据2021年ESC临床实践指南，共有38.3%的患者被归类为非常高风险，51.9%为高风险，9.8%为中度风险，分别有22.0%，29.7%和47.6%的患者达到LDL-c目标。根据2023年临床实践指南，43.0%为非常高风险；25.7%为高危人群；中度风险24.8%；低危组为6.5%，分别达到了21.7%、29.1%、54.7%和71.4%的LDL-c目标。32.7%的患者风险分级发生改变。在治疗方面，23.83%的患者未接受降脂治疗，26.17%的患者使用高强度他汀类药物。结论T2DM患者的脂质控制仍不理想，尤其是高危患者。在不断改进的同时，SCORE2-Diabetes等工具可能会改善个体化治疗并减少心血管事件。

{"title":"Lipid management in individuals with type 2 diabetes mellitus: Analysis of a hospital-based series","authors":"João D. Martins, Débora Silveira, Henrique Pina, Inês Manique, Sílvia Guerra, Cristina Valadas","doi":"10.1016/j.endinu.2025.501674","DOIUrl":"10.1016/j.endinu.2025.501674","url":null,"abstract":"<div><h3>Background and aims</h3><div>People with type 2 diabetes (T2DM) face higher cardiovascular risk, making lipid control essential. The European Society of Cardiology (ESC) updated its clinical practice guidelines in 2023, introducing the SCORE2-Diabetes risk calculator. This study evaluates lipid control, lipid-lowering therapy, and CV risk reclassification in full compliance with the 2021 and 2023 ESC clinical practice guidelines.</div></div><div><h3>Methods and results</h3><div>We analyzed T2DM patients (40–69 years) treated at our hospital Endocrinology-Diabetes outpatient clinic from January through October 2023. Hospital records and the Portuguese National Health System database were used to assess CV risk, LDL-c target achievement, risk classification changes, and lipid-lowering therapy, including statin potency. The study included a total of 214 individuals (mean age, 58.5 years; 61.2% men). Under the 2021 ESC clinical practice guidelines, a total of 38.3% patients were categorized as very high risk, 51.9% as high risk, and 9.8% as moderate risk, with LDL-c targets met in 22.0%, 29.7%, and 47.6%, respectively. Under the 2023 clinical practice guidelines, 43.0% were very high risk; 25.7%, high risk; 24.8%, moderate risk; and 6.5%, low risk, with LDL-c targets met in 21.7%, 29.1%, 54.7%, and 71.4%, respectively. Risk classification changed for 32.7% of patients. Regarding treatment, 23.83% were not on lipid-lowering therapy, while 26.17% used high-intensity statins.</div></div><div><h3>Conclusion</h3><div>Lipid control in T2DM remains suboptimal, especially in high-risk patients. While improvements are being made, tools such as the SCORE2-Diabetes may improve individualized treatment and reduce cardiovascular events.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501674"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Satisfacción asociada a la terapia hormonal de afirmación de género 与性别肯定激素疗法相关的满意度

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-03 DOI: 10.1016/j.endinu.2025.501688

Lucía Estévez Asensio , Esther Delgado García , Marina Gómez Andrés , María Samaniego Montoro , Antonia Maniega Rubio , Carmen Fernández Rodríguez , Ruth González Collantes , María José Bartolomé Albistegui , Marta Alonso Mesonero , Ana Belén Casas Marcos , Daniel A. de Luis Román , Emilia Gómez Hoyos

Introduction

Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).

Material and methods

Cross-sectional observational study among transgender individuals who had been receiving GAHT for >1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.

Results

Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17–25] years, with a median treatment duration of 3 [1.75–4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the “perceived problem solution” domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).

Conclusions

Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.

性别确认激素疗法（GAHT）改善心理健康和某些生活质量参数。然而，接受这种治疗的个体所感受到的满足感尚不清楚。本研究的目的是使用西班牙语接受治疗满意度量表（CRES-4）来评估这种满意度。材料和方法在接受GAHT治疗1年且未做过生殖器重置手术的跨性别者中进行横断面观察研究。参与者在2014年1月至2023年1月期间从跨性别医学单位招募。收集了人口统计学和临床数据，以及对CRES-4量表的反应。使用SPSS-V-23进行统计分析。结果83名被试中，男性变性者52人（62.7%），女性变性者31人（37.3%）。接受GAHT治疗的中位年龄为19[17-25]岁，评估时的中位治疗时间为3[1.75-4]年。95%的参与者报告对GAHT感到满意，75%的人注意到“感知问题解决方案”领域的改善。情绪健康显著改善，68%的人报告在GAHT后情绪状态可接受，而开始治疗前只有9%。满意度与治疗时间、心理合并症、开始治疗的年龄、非生殖器性别确认手术或激素治疗类型（女性化与男性化）没有显著相关。结论：大多数跨性别者报告称，当将GAHT作为综合生物心理社会护理的一部分时，他们对GAHT的满意度很高。这种疗法改善了情绪健康，增强了对问题解决的感知。

{"title":"Satisfacción asociada a la terapia hormonal de afirmación de género","authors":"Lucía Estévez Asensio , Esther Delgado García , Marina Gómez Andrés , María Samaniego Montoro , Antonia Maniega Rubio , Carmen Fernández Rodríguez , Ruth González Collantes , María José Bartolomé Albistegui , Marta Alonso Mesonero , Ana Belén Casas Marcos , Daniel A. de Luis Román , Emilia Gómez Hoyos","doi":"10.1016/j.endinu.2025.501688","DOIUrl":"10.1016/j.endinu.2025.501688","url":null,"abstract":"<div><h3>Introduction</h3><div>Gender Affirming Hormone Therapy (GAHT) improves psychological well-being and certain quality-of-life parameters. Nevertheless, the satisfaction perceived by individuals undergoing this treatment remains unclear. The aim of this study was to assess such satisfaction using the Spanish adaptation of the received treatment satisfaction scale (CRES-4).</div></div><div><h3>Material and methods</h3><div>Cross-sectional observational study among transgender individuals who had been receiving GAHT for>1 year and had not undergone genital reassignment surgery. Participants were recruited from a Transgender Medicine Unit between January 2014 and January 2023. Demographic and clinical data were collected, along with responses to the CRES-4 scale. Statistical analysis performed using SPSS-V-23.</div></div><div><h3>Results</h3><div>Out of the 83 subjects included, 52 (62.7%) were identified as transgender men and 31 (37.3%) as transgender women. The median age at initiation of GAHT was 19 [17–25] years, with a median treatment duration of 3 [1.75–4] years at the time of evaluation. 95% of participants reported being satisfied with GAHT and 75% noted an improvement in the “perceived problem solution” domain. Emotional well-being improved markedly, with 68% reporting an acceptable emotional state after GAHT, compared to 9% before starting treatment. Satisfaction was not significantly associated with treatment duration, psychological comorbidity, age at initiation, non-genital gender-affirming surgeries or type of hormone therapy (feminizing vs. masculinizing).</div></div><div><h3>Conclusions</h3><div>Most transgender individuals reported high levels of satisfaction with GAHT when provided as part of comprehensive biopsychosocial care. The therapy improved emotional well-being and enhanced perceptions of problem resolution.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501688"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147411893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impacto de la semaglutida oral en la calidad de vida y parámetros metabólicos de los pacientes con diabetes mellitus tipo 2: un estudio observacional multicéntrico 口服谷氨酸对2型糖尿病患者生活质量和代谢参数的影响：一项多中心观察性研究

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-12 DOI: 10.1016/j.endinu.2025.501713

Javier Lago Garma , Cristina Gil Mouce , Nazareth Rodríguez Novo , Olaia Díaz Trastoy , Alicia Santamaría Nieto , Patricia Pérez Castro , Carmen Díaz Ortega , Eva Fernández Rodríguez , Regina Palmeiro Carballeira , Iria Pinal Osorio , Alma Prieto Tenreiro , Paula Sánchez Sobrino , Cristina Tejera Pérez , Francisco Pita Gutiérrez , Rocío Villar Taibo , Alfonso Vidal Casariego

Introduction

Type 2 diabetes mellitus (T2DM) significantly impacts the patients’ quality of life due to chronic complications and associated comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in glycemic control. This study evaluates the effect of oral semaglutide on quality of life, metabolic parameters, and treatment adherence of T2DM patients.

Patients and methods

We conducted a multicenter prospective observational study Galicia (Spain). A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters. Changes in quality of life, HbA1c, weight, lipid profile, and insulin dose were analyzed.

Results

Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; P<.001) and DTSQ questionnaire (from 28.2 to 33.0 points; P<.001). Significant reductions were observed in HbA1c (8.3% to 7.2%; P<.001) and body weight (−4.9%; P=.018). The most common adverse effects were nausea and vomiting, reported by 39.5% of patients, with no impact on the overall quality of life.

Conclusion

Oral semaglutide significantly improves quality of life and metabolic parameters in T2DM patients, with good tolerance and low discontinuation rates. These findings support its utility in the comprehensive management of T2DM.

2型糖尿病（T2DM）的慢性并发症及相关合并症显著影响患者的生活质量。胰高血糖素样肽-1受体激动剂（GLP-1 RAs）已被证明对血糖控制有益。本研究评估口服西马鲁肽对T2DM患者生活质量、代谢参数和治疗依从性的影响。患者和方法我们在加利西亚（西班牙）进行了一项多中心前瞻性观察性研究。在基线和3-6个月后，使用有效问卷（DTSQ和EuroQol）、人体测量和代谢参数对43例口服西马鲁肽的成年T2DM患者进行评估。分析生活质量、糖化血红蛋白、体重、血脂和胰岛素剂量的变化。结果根据视觉模拟量表（62.8 ~ 72.6分；P<.001）和DTSQ问卷（28.2 ~ 33.0分；P<.001），口服西马鲁肽可显著改善患者的生活质量。HbA1c （8.3% - 7.2%; P<.001）和体重（- 4.9%；P=.018）显著降低。最常见的不良反应是恶心和呕吐，39.5%的患者报告，对整体生活质量没有影响。结论口服西马鲁肽可显著改善T2DM患者的生活质量和代谢指标，耐受性好，停药率低。这些发现支持其在T2DM综合管理中的应用。

{"title":"Impacto de la semaglutida oral en la calidad de vida y parámetros metabólicos de los pacientes con diabetes mellitus tipo 2: un estudio observacional multicéntrico","authors":"Javier Lago Garma , Cristina Gil Mouce , Nazareth Rodríguez Novo , Olaia Díaz Trastoy , Alicia Santamaría Nieto , Patricia Pérez Castro , Carmen Díaz Ortega , Eva Fernández Rodríguez , Regina Palmeiro Carballeira , Iria Pinal Osorio , Alma Prieto Tenreiro , Paula Sánchez Sobrino , Cristina Tejera Pérez , Francisco Pita Gutiérrez , Rocío Villar Taibo , Alfonso Vidal Casariego","doi":"10.1016/j.endinu.2025.501713","DOIUrl":"10.1016/j.endinu.2025.501713","url":null,"abstract":"<div><h3>Introduction</h3><div>Type 2 diabetes mellitus (T2DM) significantly impacts the patients’ quality of life due to chronic complications and associated comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated benefits in glycemic control. This study evaluates the effect of oral semaglutide on quality of life, metabolic parameters, and treatment adherence of T2DM patients.</div></div><div><h3>Patients and methods</h3><div>We conducted a multicenter prospective observational study Galicia (Spain). A total of 43 adult T2DM patients on oral semaglutide were evaluated at baseline and 3-6 months later using validated questionnaires (DTSQ and EuroQol), anthropometric measures, and metabolic parameters. Changes in quality of life, HbA1c, weight, lipid profile, and insulin dose were analyzed.</div></div><div><h3>Results</h3><div>Oral semaglutide significantly improved quality of life according to the visual analog scale (from 62.8 to 72.6 points; <em>P</em><.001) and DTSQ questionnaire (from 28.2 to 33.0 points; <em>P</em><.001). Significant reductions were observed in HbA1c (8.3% to 7.2%; <em>P</em><.001) and body weight (−4.9%; <em>P</em>=.018). The most common adverse effects were nausea and vomiting, reported by 39.5% of patients, with no impact on the overall quality of life.</div></div><div><h3>Conclusion</h3><div>Oral semaglutide significantly improves quality of life and metabolic parameters in T2DM patients, with good tolerance and low discontinuation rates. These findings support its utility in the comprehensive management of T2DM.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501713"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hipotiroidismo refractario y tratamiento con levotiroxina subcutánea: a propósito de un caso 难治性甲状腺功能减退和皮下左旋甲状腺素治疗：以病例为例

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-05 DOI: 10.1016/j.endinu.2025.501689

Isabella Mattei, María Calatayud Gutiérrez, Carla Jimena Santiváñez Pérez

引用次数: 0

Sudomotor dysfunction in type 1 diabetes: A case report 1型糖尿病sudommotor功能障碍1例报告

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-13 DOI: 10.1016/j.endinu.2025.501715

Juan A. García-Arnés , Lidia Fernández-Díaz , Fatima Herrera-Pérez , Natalia García-Casares , Marc S. Dawid-Milner

Sudomotor dysfunction is a frequent and early sign of diabetic neuropathy. It is a disorder of the autonomic nervous system that involves small fibers and is usually underdiagnosed despite the impact it has on the patients’ quality of life. Its study is recommended as a strategy for early detection as an indicator of dysautonomic dysfunction and management of later complications. Although it can be highly disabling, it often goes unnoticed, as it is considered less alarming than other dysautonomic symptoms. We present the case of a diabetic patient with sudomotor disfunction who underwent a comprehensive autonomic nervous system evaluation. Unlike most related studies, this case highlights a combination of compensatory hyperhidrosis and distal anhidrosis, underscoring the variability in clinical signs of sudomotor dysfunction. Additionally, it demonstrates the importance of autonomic testing in differential diagnosis and emphasizes the need for further research into its pathophysiological mechanisms and effective therapeutic strategies.

支配运动功能障碍是糖尿病性神经病变的常见早期症状。这是一种涉及小纤维的自主神经系统疾病，尽管它对患者的生活质量有影响，但通常未被诊断出来。它的研究被推荐作为一种策略，作为自主神经异常功能障碍的早期检测指标和后期并发症的管理。虽然它可能是高度致残的，但它经常被忽视，因为它被认为没有其他自主神经异常症状那么令人担忧。我们提出的情况下，糖尿病患者与sudymotor功能障碍谁接受了全面的自主神经系统评估。与大多数相关研究不同，本病例强调代偿性多汗症和远端无汗症的结合，强调了sudomotor功能障碍临床症状的可变性。此外，它证明了自主神经测试在鉴别诊断中的重要性，并强调需要进一步研究其病理生理机制和有效的治疗策略。

{"title":"Sudomotor dysfunction in type 1 diabetes: A case report","authors":"Juan A. García-Arnés , Lidia Fernández-Díaz , Fatima Herrera-Pérez , Natalia García-Casares , Marc S. Dawid-Milner","doi":"10.1016/j.endinu.2025.501715","DOIUrl":"10.1016/j.endinu.2025.501715","url":null,"abstract":"<div><div>Sudomotor dysfunction is a frequent and early sign of diabetic neuropathy. It is a disorder of the autonomic nervous system that involves small fibers and is usually underdiagnosed despite the impact it has on the patients’ quality of life. Its study is recommended as a strategy for early detection as an indicator of dysautonomic dysfunction and management of later complications. Although it can be highly disabling, it often goes unnoticed, as it is considered less alarming than other dysautonomic symptoms. We present the case of a diabetic patient with sudomotor disfunction who underwent a comprehensive autonomic nervous system evaluation. Unlike most related studies, this case highlights a combination of compensatory hyperhidrosis and distal anhidrosis, underscoring the variability in clinical signs of sudomotor dysfunction. Additionally, it demonstrates the importance of autonomic testing in differential diagnosis and emphasizes the need for further research into its pathophysiological mechanisms and effective therapeutic strategies.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501715"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cáncer anaplásico de tiroides que responde a tratamiento con inhibidor RET 对RET抑制剂治疗有反应的变性甲状腺癌

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-26 DOI: 10.1016/j.endinu.2025.501690

Carlos Ríos Gómez , Alicia Macías Batista , Ignacio García Puente , Laura Esther Guerrero Casanova , Miguel Carnero Gregorio

引用次数: 0

Estudio de la prevalencia de casos de obesidad y sedentarismo en edad escolar en el Área Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz 赫雷斯、西北海岸和加的斯山脉卫生区学龄肥胖和久坐症流行情况研究

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-14 DOI: 10.1016/j.endinu.2025.501691

Josefa Rojas Villegas , Lourdes Garcia Garcia-Doncel , Maria Angeles Santos Mata , Yolanda Quirós López , Isabel Morón Rubio

引用次数: 0

Apoplejía hipofisaria: lecciones del registro español para una estratificación clínica apoyada en imagen avanzada 下垂体性中风：西班牙注册高级成像支持临床分层的经验教训

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2026-02-23 DOI: 10.1016/j.endinu.2026.501779

Betina Biagetti

引用次数: 0

Health care resource utilization among individuals with diabetes in Spain: Trends from population-based surveys, 2014–2020 西班牙糖尿病患者的医疗保健资源利用：2014-2020年基于人群调查的趋势

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-10-17 DOI: 10.1016/j.endinu.2025.501684

Luyi Zeng-Zhang , Natividad Cuadrado-Corrales , Rodrigo Jiménez-García , Ana López-de-Andrés , Zichen Ji , Jose J. Zamorano-León , Andrés Bodas-Pinedo , Ana Jiménez-Sierra , Elena Labajo-Gonzalez , Javier de Miguel-Diez

Background

Diabetes mellitus (DM) has a high health care burden. Understanding health care resource use in DM is essential for optimizing services. This study examines health care utilization among individuals with DM in Spain, comparing them to individuals without DM.

Methods

This study analyzed data from the 2014 and 2020 European Interview Health Survey for Spain (EHISS). Participants who reported a diagnosis of DM were classified as cases and matched to controls without DM by sex, age, EHISS edition and place of residence. The dependent variables studied were hospitalizations and emergency department visits during the 12 months. Independent variables included sociodemographics, lifestyle, and comorbidity factors.

Results

The study included a total of 7854 participants (3927 cases and 3927 controls). A comparison between 2014 and 2020 showed fewer hospitalizations (19.0% vs 16.1%, p = 0.018) and emergency department visits (36.2% vs 28.7%, p < 0.001) among individuals with DM. Individuals with DM had significantly higher rates of hospitalization (17.5% vs 11.1%; p < 0.001) and emergency department visits (32.3% vs 24.6%; p < 0.001) vs those without DM. The identified common predictors of hospitalization and emergency department visits were poor self-rated health and cardiac ischemia.

Conclusion

We observed a higher health care utilization among individuals with DM and a downward trend from 2014 to 2020. Identifying predictors of health care use may facilitate the development of interventions to reduce health care costs. The results should be interpreted with caution due to limitations, particularly the lack of data on DM type and glycemic control.

背景糖尿病（DM）具有很高的医疗负担。了解糖尿病患者的卫生保健资源使用情况对于优化服务至关重要。本研究调查了西班牙糖尿病患者的医疗保健利用情况，并将其与非糖尿病患者进行了比较。方法本研究分析了2014年和2020年西班牙欧洲访谈健康调查（EHISS）的数据。报告诊断为糖尿病的参与者被分类为病例，并根据性别、年龄、EHISS版本和居住地与未患糖尿病的对照组相匹配。研究的因变量是12个月内的住院和急诊就诊情况。独立变量包括社会人口统计学、生活方式和合并症因素。结果共纳入7854名受试者（病例3927例，对照组3927例）。2014年和2020年的比较显示，糖尿病患者的住院率（19.0%对16.1%,p = 0.018）和急诊科就诊率（36.2%对28.7%,p < 0.001）更少。糖尿病患者的住院率（17.5%对11.1%,p < 0.001）和急诊科就诊率(32.3%对24.6%；p < 0.001)与没有糖尿病的患者相比。确定的住院和急诊就诊的共同预测因素是自我评价健康状况不佳和心脏缺血。结论2014 - 2020年糖尿病患者的医疗保健使用率呈上升趋势，且呈下降趋势。确定卫生保健使用的预测因素可能有助于制定降低卫生保健费用的干预措施。由于局限性，特别是缺乏糖尿病类型和血糖控制的数据，对结果的解释应谨慎。

{"title":"Health care resource utilization among individuals with diabetes in Spain: Trends from population-based surveys, 2014–2020","authors":"Luyi Zeng-Zhang , Natividad Cuadrado-Corrales , Rodrigo Jiménez-García , Ana López-de-Andrés , Zichen Ji , Jose J. Zamorano-León , Andrés Bodas-Pinedo , Ana Jiménez-Sierra , Elena Labajo-Gonzalez , Javier de Miguel-Diez","doi":"10.1016/j.endinu.2025.501684","DOIUrl":"10.1016/j.endinu.2025.501684","url":null,"abstract":"<div><h3>Background</h3><div>Diabetes mellitus (DM) has a high health care burden. Understanding health care resource use in DM is essential for optimizing services. This study examines health care utilization among individuals with DM in Spain, comparing them to individuals without DM.</div></div><div><h3>Methods</h3><div>This study analyzed data from the 2014 and 2020 European Interview Health Survey for Spain (EHISS). Participants who reported a diagnosis of DM were classified as cases and matched to controls without DM by sex, age, EHISS edition and place of residence. The dependent variables studied were hospitalizations and emergency department visits during the 12 months. Independent variables included sociodemographics, lifestyle, and comorbidity factors.</div></div><div><h3>Results</h3><div>The study included a total of 7854 participants (3927 cases and 3927 controls). A comparison between 2014 and 2020 showed fewer hospitalizations (19.0% vs 16.1%, <em>p</em>  <0.001) among individuals with DM. Individuals with DM had significantly higher rates of hospitalization (17.5% vs 11.1%; <em>p</em>  <0.001) vs those without DM. The identified common predictors of hospitalization and emergency department visits were poor self-rated health and cardiac ischemia.</div></div><div><h3>Conclusion</h3><div>We observed a higher health care utilization among individuals with DM and a downward trend from 2014 to 2020. Identifying predictors of health care use may facilitate the development of interventions to reduce health care costs. The results should be interpreted with caution due to limitations, particularly the lack of data on DM type and glycemic control.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501684"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Looking into the future: The updated Endocrinology and Nutrition residency training program in Spain 展望未来：最新的内分泌学和营养学住院医师培训计划在西班牙

4区医学 Q3 Nursing

Endocrinologia, Diabetes y Nutricion

Pub Date : 2026-03-01 Epub Date: 2025-11-10 DOI: 10.1016/j.endinu.2025.501714

María D. Ballesteros-Pomar , María Antequera , Manuel Antonio Botana-López , Pilar Beato-Víbora , Luis Eduardo Lander , Paloma Moreno-Moreno , Juan Francisco Merino-Torres , Joana Nicolau , Luis Vázquez , Manel Puig-Domingo

Background

Endocrinology and Nutrition residency training in Spain (MIR program) is undergoing a major update for the first time since 2006, reflecting rapid advances in endocrine science, technology, and educational standards. Internationally, the European Society of Endocrinology (ESE) has introduced a unified curriculum to harmonize specialist training across Europe, highlighting core competencies and the need for longer training. This article outlines the renewed Spanish Endocrinology-Nutrition MIR program proposal, detailing its modernized curriculum, innovative assessment methods, and the debate on extending training duration.

Advances in modern endocrinology

The updated program highlights emerging areas such as molecular endocrinology, technology-enhanced diabetes care, diagnosis and prevention of arteriosclerotic vascular disease, metabolism and rare endocrine disorders, multidisciplinary obesity management, and the central role of nutrition in patient care. These priorities reflect current trends in clinical practice and the forefront of endocrine research.

Assessment innovation

New evaluation methods focus on competency-based training, with progressive responsibility, portfolios, workplace-based assessments and entrustable professional activities (EPAs) to ensure trainees attain defined skills. Formal examinations and objective assessments are introduced to standardize certification.

Training duration

A pivotal discussion is whether to extend the residency from 4 to 5 years. Given the breadth of endocrinology and ESE recommendations of a 6-year combined internal medicine–endocrinology training, Spanish experts argue a 5th year is “reasonable” to accommodate new technologies and growing complexity although no consensus has been attained so far.

Conclusion

The renewed program aligns with international standards and future-proofs endocrinologist training. It balances broad endocrine-nutrition competencies with specialized skills, modern assessment, and potentially longer training to produce experts equipped for evolving healthcare needs.

西班牙内分泌学和营养学住院医师培训（MIR项目）自2006年以来首次经历重大更新，反映了内分泌科学、技术和教育标准的快速进步。在国际上，欧洲内分泌学会（ESE）引入了统一的课程，以协调整个欧洲的专家培训，强调核心能力和长期培训的必要性。本文概述了更新的西班牙内分泌营养学MIR项目提案，详细介绍了其现代化的课程，创新的评估方法，以及关于延长培训时间的辩论。现代内分泌学的进展更新后的课程重点介绍了一些新兴领域，如分子内分泌学、技术增强的糖尿病护理、动脉硬化性血管疾病的诊断和预防、代谢和罕见内分泌紊乱、多学科肥胖管理以及营养在患者护理中的核心作用。这些优先事项反映了临床实践的当前趋势和内分泌研究的前沿。评估创新新的评估方法侧重于以能力为基础的培训，采用渐进式责任、组合、基于工作场所的评估和可信赖的专业活动（EPAs），以确保受训者获得规定的技能。引入正式考试和客观评估来规范认证。一个关键的讨论是是否将住院医师实习期从4年延长到5年。鉴于内分泌学的广度和ESE建议的6年内科-内分泌学联合培训，西班牙专家认为，第5年是“合理的”，以适应新技术和日益复杂的情况，尽管迄今尚未达成共识。结论更新后的方案符合国际标准和面向未来的内分泌学家培训。它平衡了广泛的内分泌营养能力与专业技能，现代评估和潜在的更长的培训，以产生专家装备不断变化的医疗保健需求。

{"title":"Looking into the future: The updated Endocrinology and Nutrition residency training program in Spain","authors":"María D. Ballesteros-Pomar , María Antequera , Manuel Antonio Botana-López , Pilar Beato-Víbora , Luis Eduardo Lander , Paloma Moreno-Moreno , Juan Francisco Merino-Torres , Joana Nicolau , Luis Vázquez , Manel Puig-Domingo","doi":"10.1016/j.endinu.2025.501714","DOIUrl":"10.1016/j.endinu.2025.501714","url":null,"abstract":"<div><h3>Background</h3><div>Endocrinology and Nutrition residency training in Spain (MIR program) is undergoing a major update for the first time since 2006, reflecting rapid advances in endocrine science, technology, and educational standards. Internationally, the European Society of Endocrinology (ESE) has introduced a unified curriculum to harmonize specialist training across Europe, highlighting core competencies and the need for longer training. This article outlines the renewed Spanish Endocrinology-Nutrition MIR program proposal, detailing its modernized curriculum, innovative assessment methods, and the debate on extending training duration.</div></div><div><h3>Advances in modern endocrinology</h3><div>The updated program highlights emerging areas such as molecular endocrinology, technology-enhanced diabetes care, diagnosis and prevention of arteriosclerotic vascular disease, metabolism and rare endocrine disorders, multidisciplinary obesity management, and the central role of nutrition in patient care. These priorities reflect current trends in clinical practice and the forefront of endocrine research.</div></div><div><h3>Assessment innovation</h3><div>New evaluation methods focus on competency-based training, with progressive responsibility, portfolios, workplace-based assessments and entrustable professional activities (EPAs) to ensure trainees attain defined skills. Formal examinations and objective assessments are introduced to standardize certification.</div></div><div><h3>Training duration</h3><div>A pivotal discussion is whether to extend the residency from 4 to 5 years. Given the breadth of endocrinology and ESE recommendations of a 6-year combined internal medicine–endocrinology training, Spanish experts argue a 5th year is “reasonable” to accommodate new technologies and growing complexity although no consensus has been attained so far.</div></div><div><h3>Conclusion</h3><div>The renewed program aligns with international standards and future-proofs endocrinologist training. It balances broad endocrine-nutrition competencies with specialized skills, modern assessment, and potentially longer training to produce experts equipped for evolving healthcare needs.</div></div>","PeriodicalId":37725,"journal":{"name":"Endocrinologia, Diabetes y Nutricion","volume":"73 3","pages":"Article 501714"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147412156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Endocrinologia, Diabetes y Nutricion

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀